{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T23:50:30Z","timestamp":1675727430839},"reference-count":36,"publisher":"FapUNIFESP (SciELO)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Radiol Bras"],"abstract":"<jats:p>Abstract Objective: To compare the degree of benign bone marrow uptake of 18F-fluorodeoxyglucose (18F-FDG) between Hodgkin lymphoma patients with and without B symptoms. Materials and Methods: We analyzed the medical charts of 74 Hodgkin lymphoma patients who underwent 18F-FDG positron emission tomography\/computed tomography (PET\/CT) prior to the initiation of therapy between October 2010 and September 2013. In all of the patients, the bone marrow biopsy was negative and the 18F-FDG PET\/CT images did not suggest bone marrow involvement. Of the 74 patients evaluated, 54 presented inflammatory (B) symptoms and 20 did not. Regions of interest (ROIs) were drawn on the sternum, the proximal thirds of the humeri, the proximal thirds of the femora, and both iliac wings (totaling seven ROIs per patient). To compare the patients with and without B symptoms, in terms of standardized uptake values (SUVs) for the seven ROIs, we used the Mann-Whitney U test. Results: For six of the ROIs, the SUVs were higher in the patients with B symptoms than in those without, and the difference was statistically significant (p &lt; 0.05). There was also a tendency toward a statistically significant difference between the two groups in terms of the SUV for the right iliac wing ROI (p = 0.06). Conclusion: In our sample, the presence of B symptoms was associated with increased 18F-FDG uptake in bone marrow.<\/jats:p>","DOI":"10.1590\/0100-3984.2016.0201","type":"journal-article","created":{"date-parts":[[2018,3,3]],"date-time":"2018-03-03T23:10:09Z","timestamp":1520118609000},"page":"78-80","source":"Crossref","is-referenced-by-count":1,"title":["Bone marrow uptake of 18F-fluorodeoxyglucose in Hodgkin lymphoma without bone involvement: comparison between patients with and without B symptoms"],"prefix":"10.1590","volume":"51","author":[{"given":"R\u00f4mulo Hermeto Bueno do","family":"Vale","sequence":"first","affiliation":[{"name":"Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela Andrade","family":"Ferraro","sequence":"additional","affiliation":[{"name":"Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo Schiavom","family":"Duarte","sequence":"additional","affiliation":[{"name":"Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovana","family":"Carvalho","sequence":"additional","affiliation":[{"name":"Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos Santos","family":"Lima","sequence":"additional","affiliation":[{"name":"Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George Barb\u00e9rio","family":"Coura Filho","sequence":"additional","affiliation":[{"name":"Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo Tatit","family":"Sapienza","sequence":"additional","affiliation":[{"name":"Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Alberto","family":"Buchpiguel","sequence":"additional","affiliation":[{"name":"Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","published-online":{"date-parts":[[2018,3,1]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1056\/NEJMe078173","article-title":"Hodgkin's disease-from pathology specimen to cure","volume":"357","author":"Diehl V","year":"2007","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"6400","DOI":"10.1200\/JCO.2005.05.016","article-title":"State-of-the-art therapeutics: Hodgkin's lymphoma","volume":"23","author":"Connors JM","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"ix71","DOI":"10.1093\/annonc\/mdm297","article-title":"Early, intermediate and advanced Hodgkin's lymphoma: modern treatment strategies","volume":"18","author":"Diehl V","year":"2007","journal-title":"Ann Oncol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1600-0609.2005.00467.x","article-title":"The EORTC strategy in the treatment of Hodgkin's lymphoma","volume":"66","author":"Eghbali H","year":"2005","journal-title":"Eur J Haematol Suppl"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1002\/cncr.24178","article-title":"Survival after Hodgkin lymphoma: causes of death and excess mortality in patients treated in 8 consecutive trials","volume":"115","author":"Favier O","year":"2009","journal-title":"Cancer"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","article-title":"Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting","volume":"7","author":"Lister TA","year":"1989","journal-title":"J Clin Oncol"},{"key":"ref7","first-page":"1860","article-title":"Report of the Committee on Hodgkin's Disease Staging Classification","volume":"31","author":"Carbone PP","year":"1971","journal-title":"Cancer Res"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1182\/blood.V98.10.2930","article-title":"Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease","volume":"98","author":"Weihrauch MR","year":"2001","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington SF","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1200\/JCO.2008.19.7814","article-title":"Early and late therapy response assessment with [18F]fluorodeoxyglucose positron emission tomography in pediatric Hodgkin's lymphoma: analysis of a prospective multicenter trial","volume":"27","author":"Furth C","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","article-title":"Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study","volume":"25","author":"Gallamini A","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref12","first-page":"482","article-title":"Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma","volume":"91","author":"Hutchings M","year":"2006","journal-title":"Haematologica"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.radonc.2008.05.012","article-title":"The conundrum of Hodgkin lymphoma nodes: to be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines","volume":"88","author":"Girinsky T","year":"2008","journal-title":"Radiother Oncol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1182\/blood.V91.9.3340","article-title":"Detection of lymphoma in bone marrow by whole-body positron emission tomography","volume":"91","author":"Carr R","year":"1998","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1177\/014107689909200410","article-title":"Bone marrow involvement in breast cancer detected by positron emission tomography","volume":"92","author":"Lewanski CR","year":"1999","journal-title":"J R Soc Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1007\/s00259-005-1890-0","article-title":"Effect of colony-stimulating factor and conventional- or high-dose chemotherapy on FDG uptake in bone marrow","volume":"32","author":"Kazama T","year":"2005","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/01.rlu.0000115654.90324.02","article-title":"Diffuse bone marrow uptake on whole-body F-18 fluorodeoxyglucose positron emission tomography in a patient taking recombinant erythropoietin","volume":"29","author":"Blodgett TM","year":"2004","journal-title":"Clin Nucl Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/00003072-200410000-00010","article-title":"Diffuse bone marrow accumulation of FDG in a patient with chronic myeloid leukemia mimics hematopoietic cytokine-mediated FDG uptake on positron emission tomography","volume":"29","author":"Takalkar A","year":"2004","journal-title":"Clin Nucl Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/01.rlu.0000178029.47624.66","article-title":"Myelofibrosis on F-18 FDG PET imaging","volume":"30","author":"Burrell SC","year":"2005","journal-title":"Clin Nucl Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00259-014-2706-x","article-title":"Characterizing bone marrow involvement in Hodgkin's lymphoma by FDG-PET\/CT","volume":"41","author":"Weiler-Sagie M","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1590\/0100-3984.2014.0012","article-title":"Solitary pulmonary nodule and 18F-FDG PET\/CT. Part 1: epidemiology, morphological evaluation and cancer probability","volume":"49","author":"Mosmann MP","year":"2016","journal-title":"Radiol Bras"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1590\/0100-3984.2014.0087","article-title":"Solitary pulmonary nodule and 18F-FDG PET\/CT. Part 2: accuracy, cost-effectiveness, and current recommendations","volume":"49","author":"Mosmann MP","year":"2016","journal-title":"Radiol Bras"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1590\/0100-3984.2015.0172","article-title":"Complementary findings on 18F-FDG PET\/CT and 18F-NaF PET\/CT in a patient with Erdheim-Chester disease","volume":"50","author":"Sabino D","year":"2017","journal-title":"Radiol Bras"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1590\/0100-3984.2015-0232","article-title":"Detection of distant metastases in patients with locally advanced breast cancer: role of 18F-fluorodeoxyglucose positron emission tomography\/computed tomography and conventional imaging with computed tomography scans","volume":"50","author":"Bitencourt AGV","year":"2017","journal-title":"Radiol Bras"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1590\/0100-3984.2016.0076","article-title":"SPECT\/CT with radiolabeled somatostatin analogues in the evaluation of systemic granulomatous infections","volume":"50","author":"Monteiro PHS","year":"2017","journal-title":"Radiol Bras"},{"key":"ref26","first-page":"126","article-title":"Incidental diagnosis of struma ovarii through radioiodine whole-body scanning: incremental role of SPECT\/CT","volume":"49","author":"Vale RHB","year":"2016","journal-title":"Radiol Bras"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1182\/blood-2002-01-0099","article-title":"The role of cytokines in classical Hodgkin lymphoma","volume":"99","author":"Skinnider BF","year":"2002","journal-title":"Blood"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1200\/JCO.2006.08.1331","article-title":"Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte","volume":"25","author":"Casasnovas RO","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref29","first-page":"191","article-title":"Serum levels of cytokines and prevalence of autoantibodies in lymphoma patients and their prognostic value","volume":"19","author":"Uskudar Teke H","year":"2014","journal-title":"J BUON"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"483","DOI":"10.5858\/2010-0060-OA.1","article-title":"Serum levels of interleukins 6, 10, and 13 before and after treatment of classic Hodgkin lymphoma","volume":"135","author":"Gaiolla RD","year":"2011","journal-title":"Arch Pathol Lab Med"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1200\/JCO.2009.27.6873","article-title":"Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin","volume":"28","author":"Hohaus S","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1038\/sj.leu.2403123","article-title":"Increased serum levels of interleukin-9 correlate to negative prognostic factors in Hodgkin's lymphoma","volume":"17","author":"Fischer M","year":"2003","journal-title":"Leukemia"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1097\/01.rlu.0000242685.55001.67","article-title":"Diffuse bone marrow uptake on F-18 FDG PET in patients with myelodysplastic syndromes","volume":"31","author":"Inoue K","year":"2006","journal-title":"Clin Nucl Med"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s00259-009-1377-5","article-title":"(18)F-FDG PET\/CT bone\/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging","volume":"37","author":"Moulin-Romsee G","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1007\/s00259-009-1183-0","article-title":"Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin's lymphoma: a reflection of disease infiltration or just inflammation?","volume":"36","author":"Salaun PY","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"5739","DOI":"10.1200\/JCO.2005.17.970","article-title":"Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials","volume":"23","author":"Shimabukuro-Vornhagen A","year":"2005","journal-title":"J Clin Oncol"}],"container-title":["Radiologia Brasileira"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/rb\/v51n2\/0100-3984-rb-20160201.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T05:23:52Z","timestamp":1660541032000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0100-39842018000200078&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,1]]},"references-count":36,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,4]]}},"alternative-id":["S0100-39842018000200078"],"URL":"https:\/\/doi.org\/10.1590\/0100-3984.2016.0201","relation":{},"ISSN":["1678-7099","0100-3984"],"issn-type":[{"value":"1678-7099","type":"electronic"},{"value":"0100-3984","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3,1]]}}}